Rankings / Hormones & Endocrine
Yohimbine
Hormones & Endocrine · Alpha-2 adrenergic antagonist
Tier C
High-risk evidence profile
Bottom line
Read Off Label grades Yohimbine as C (4.9/10) based on moderate evidence, moderate benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Yohimbine HCl and yohimbe bark are distinct — the latter has unpredictable alkaloid content including rauwolscine.
Studied, labeled, or reported-use context: 5-10 mg yohimbine HCl 2-3x/day (fat loss); 10-20 mg PRN (ED) — OTC (yohimbe bark extract — variable potency); Rx; not individualized guidance.
Citation correction in progress
1 PubMed link was found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Yohimbine HCl and yohimbe bark are distinct — the latter has unpredictable alkaloid content including rauwolscine. Strong adrenergic effects make it dangerous in anxiety-prone individuals. Pairs badly with caffeine or stimulants.
Mechanism
Alkaloid from Pausinystalia johimbe bark; selective α2-adrenergic antagonist; increases peripheral and central noradrenergic tone; historical use for ED before PDE5i era
Studied, labeled, or reported dose & route
5-10 mg yohimbine HCl 2-3x/day (fat loss); 10-20 mg PRN (ED)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Yohimbine's effects?
- Read Off Label rates the evidence for Yohimbine as Moderate and the benefit magnitude as moderate, producing an overall grade of C (4.9/10). Yohimbine HCl and yohimbe bark are distinct — the latter has unpredictable alkaloid content including rauwolscine.
- What safety findings are reported for Yohimbine?
- Yohimbine has a med-high risk profile in the database. Med-High (anxiety, panic attacks, BP spikes, tachycardia, insomnia; contraindicated with anxiety disorders, hypertension, MAOIs; can trigger PTSD flashbacks) Legal status: OTC (yohimbe bark extract — variable potency); Rx (standardized yohimbine HCl).
- What does the low Safety score for Yohimbine represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Yohimbine?
- 5-10 mg yohimbine HCl 2-3x/day (fat loss); 10-20 mg PRN (ED) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Yohimbine work?
- Alkaloid from Pausinystalia johimbe bark; selective α2-adrenergic antagonist; increases peripheral and central noradrenergic tone; historical use for ED before PDE5i era
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.